The company develops human antibodies for immunomodulation of major diseases (transplants, HIV and cancer). The company’s verified biological active human antibodies are capable of blocking or inducing apoptosis, a suicide mechanism of cells.
Contact Magnus Doverskog, CEO +46 8 524 869 24 www.imed.se
+46 8 524 869 24
